Cargando…
Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome
The aim of this study was to determine the concentration of galectin-3, PINP and PIIINP in patients with metabolic syndrome (MS) and atrial fibrillation (AF) with an assessment of the relationship with severity of left atrium fibrosis. A total of 480 subjects were included in the case-control study:...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461109/ https://www.ncbi.nlm.nih.gov/pubmed/32784491 http://dx.doi.org/10.3390/ijms21165689 |
_version_ | 1783576716566855680 |
---|---|
author | Ionin, Valery A. Baranova, Elena I. Zaslavskaya, Ekaterina L. Petrishcheva, Elena Yu. Morozov, Aleksandr N. Shlyakhto, Evgeny V. |
author_facet | Ionin, Valery A. Baranova, Elena I. Zaslavskaya, Ekaterina L. Petrishcheva, Elena Yu. Morozov, Aleksandr N. Shlyakhto, Evgeny V. |
author_sort | Ionin, Valery A. |
collection | PubMed |
description | The aim of this study was to determine the concentration of galectin-3, PINP and PIIINP in patients with metabolic syndrome (MS) and atrial fibrillation (AF) with an assessment of the relationship with severity of left atrium fibrosis. A total of 480 subjects were included in the case-control study: MS patients (n = 337), 176 of whom had AF, 72 patients with AF without MS and 71 healthy subjects. Galectin-3, PINP and PIIINP blood concentrations and metabolic parameters were compared with the severity of left atrium fibrosis, measured by CARTO3. Galectin-3 in AF and MS patients is higher than in MS without AF and in healthy subjects (10.3 (4.8–15.4), 5.1 (4.3–8.8), 3.2 (2.4–4.2) ng/mL, p < 0.0001). Galectin-3 serum concentration in AF patients with MS is higher than in patients without MS: 10.3 (4.8–15.4), 6.8 (5.2–8.1) ng/mL, p = 0.0001. PINP and PIIINP concentration were higher in patients with AF and MS than in MS without AF: 3499.1 (2299.2–4567.3), 2130.9 (1425.3–2861.8) pg/mL, p < 0.0001, 94.9 (64.8–123.5), 57.6 (40.5–86.9) ng/mL, p < 0.0001. Galectin-3 correlates with PINP (r = 0.496, p < 0.001) and PIIINP concentration (r = 0.451, p < 0.0001). The correlation between galectin-3, PINP and the severity of left atrium fibrosis was found (r = 0.410, p < 0.001; r = 0.623, p < 0.001). Galectin-3 higher than 12.6 ng/mL increased the risk of AF more than five-fold. High galectin-3, PINP and PIIINP concentrations were associated with heart remodeling in MS patients and increased the risk of AF. |
format | Online Article Text |
id | pubmed-7461109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74611092020-09-14 Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome Ionin, Valery A. Baranova, Elena I. Zaslavskaya, Ekaterina L. Petrishcheva, Elena Yu. Morozov, Aleksandr N. Shlyakhto, Evgeny V. Int J Mol Sci Article The aim of this study was to determine the concentration of galectin-3, PINP and PIIINP in patients with metabolic syndrome (MS) and atrial fibrillation (AF) with an assessment of the relationship with severity of left atrium fibrosis. A total of 480 subjects were included in the case-control study: MS patients (n = 337), 176 of whom had AF, 72 patients with AF without MS and 71 healthy subjects. Galectin-3, PINP and PIIINP blood concentrations and metabolic parameters were compared with the severity of left atrium fibrosis, measured by CARTO3. Galectin-3 in AF and MS patients is higher than in MS without AF and in healthy subjects (10.3 (4.8–15.4), 5.1 (4.3–8.8), 3.2 (2.4–4.2) ng/mL, p < 0.0001). Galectin-3 serum concentration in AF patients with MS is higher than in patients without MS: 10.3 (4.8–15.4), 6.8 (5.2–8.1) ng/mL, p = 0.0001. PINP and PIIINP concentration were higher in patients with AF and MS than in MS without AF: 3499.1 (2299.2–4567.3), 2130.9 (1425.3–2861.8) pg/mL, p < 0.0001, 94.9 (64.8–123.5), 57.6 (40.5–86.9) ng/mL, p < 0.0001. Galectin-3 correlates with PINP (r = 0.496, p < 0.001) and PIIINP concentration (r = 0.451, p < 0.0001). The correlation between galectin-3, PINP and the severity of left atrium fibrosis was found (r = 0.410, p < 0.001; r = 0.623, p < 0.001). Galectin-3 higher than 12.6 ng/mL increased the risk of AF more than five-fold. High galectin-3, PINP and PIIINP concentrations were associated with heart remodeling in MS patients and increased the risk of AF. MDPI 2020-08-08 /pmc/articles/PMC7461109/ /pubmed/32784491 http://dx.doi.org/10.3390/ijms21165689 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ionin, Valery A. Baranova, Elena I. Zaslavskaya, Ekaterina L. Petrishcheva, Elena Yu. Morozov, Aleksandr N. Shlyakhto, Evgeny V. Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome |
title | Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome |
title_full | Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome |
title_fullStr | Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome |
title_full_unstemmed | Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome |
title_short | Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome |
title_sort | galectin-3, n-terminal propeptides of type i and iii procollagen in patients with atrial fibrillation and metabolic syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461109/ https://www.ncbi.nlm.nih.gov/pubmed/32784491 http://dx.doi.org/10.3390/ijms21165689 |
work_keys_str_mv | AT ioninvalerya galectin3nterminalpropeptidesoftypeiandiiiprocollageninpatientswithatrialfibrillationandmetabolicsyndrome AT baranovaelenai galectin3nterminalpropeptidesoftypeiandiiiprocollageninpatientswithatrialfibrillationandmetabolicsyndrome AT zaslavskayaekaterinal galectin3nterminalpropeptidesoftypeiandiiiprocollageninpatientswithatrialfibrillationandmetabolicsyndrome AT petrishchevaelenayu galectin3nterminalpropeptidesoftypeiandiiiprocollageninpatientswithatrialfibrillationandmetabolicsyndrome AT morozovaleksandrn galectin3nterminalpropeptidesoftypeiandiiiprocollageninpatientswithatrialfibrillationandmetabolicsyndrome AT shlyakhtoevgenyv galectin3nterminalpropeptidesoftypeiandiiiprocollageninpatientswithatrialfibrillationandmetabolicsyndrome |